Is VERTEX PHARMACEUTICALS INC / MA (VRTX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.8% / 30% | 5.7% / 30% | 1.8% / 30% | 4.09% / 5% | ✓ HALAL |
| DJIM | 1.8% / 33% | 5.7% / 33% | 1.8% / 33% | 4.09% / 5% | ✓ HALAL |
| MSCI | 7.9% / 33% | 25.8% / 33% | 8.0% / 33% | 4.09% / 5% | ✓ HALAL |
| S&P | 1.8% / 33% | 5.7% / 33% | 1.8% / 33% | 4.09% / 5% | ✓ HALAL |
| FTSE | 7.9% / 33% | 25.8% / 33% | 8.0% / 50% | 4.09% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 53.7% | |
| Operating Margin | 39.6% | |
| Net Margin | 32.9% | |
| Return on Equity (ROE) | 22.5% | |
| Return on Assets (ROA) | 12.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $3.6B |
| Free Cash Flow | $3.2B |
| Total Debt | $2.0B |
| Debt-to-Equity | 10.9 |
| Current Ratio | 2.9 |
| Total Assets | $25.6B |
Price & Trading
| Last Close | $453.74 |
| 50-Day MA | $468.05 |
| 200-Day MA | $438.53 |
| Avg Volume | 1.4M |
| Beta | 0.3 |
|
52-Week Range
$362.50
| |
About VERTEX PHARMACEUTICALS INC / MA (VRTX)
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Purification Calculator
As a halal stock with 4.09% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is VERTEX PHARMACEUTICALS INC / MA (VRTX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), VERTEX PHARMACEUTICALS INC / MA is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is VERTEX PHARMACEUTICALS INC / MA's debt ratio?
VERTEX PHARMACEUTICALS INC / MA's debt ratio is 1.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 7.9%.
Does VERTEX PHARMACEUTICALS INC / MA require dividend purification?
Yes, VERTEX PHARMACEUTICALS INC / MA has an impermissible income ratio of 4.09%, which means 4.09% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are VERTEX PHARMACEUTICALS INC / MA's key financial metrics?
VERTEX PHARMACEUTICALS INC / MA has a market capitalization of $110.0B, trailing P/E ratio of 28.2, and revenue of $12.0B. The company maintains a gross margin of 53.7% and a net margin of 32.9%. Return on equity stands at 22.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.